在美国DREAM关键研究中,使用Nyxoah的Genio®装置12个月后,OSA患者的AHI中位数减少了71% 71% median AHI reduction in OSA patients after 12 months with Nyxoah's Genio® device in the DREAM U.S. pivotal study.

Nyxoah的《美国梦想》的关键研究显示,12个月后,Apnea-Hypopnea 指数(AHI)中位数下降71%,用于阻塞睡眠性脑膜炎(OSA)患者。 Nyxoah's DREAM U.S. pivotal study revealed a 71% median reduction in the Apnea-Hypopnea Index (AHI) for patients with obstructive sleep apnea (OSA) after 12 months. 值得注意的是,82%的参与者的AHI低于15岁,提高了生活质量。 Notably, 82% of participants had an AHI below 15, enhancing their quality of life. Nyxoah 的 Genio® 设备是一种无电池舌下神经调控系统，现在正在向 FDA 批准迈进，有望为美国的 OSA 患者提供新的治疗选择。 Nyxoah's Genio® device, a battery-free hypoglossal neuromodulation system, is now advancing toward FDA approval, promising a new treatment option for OSA patients in the U.S.